Castle Biosciences, Inc.

that weren't being seen in person and having that mole on the back of their neck or the side of their ear be picked up ancillary, those are the ones that are being missed. And when they're coming in, our perception now is that they're coming in with a little more worsened or a little more adverse melanoma in terms of thickness. Now, what's that mean for CASL? I think one is that certainly there are some patients who have very, very thin melanomas like 0.1 millimeter 0.2 millimeters thick where we have difficulty generating data showing that we actually add value in tumors that are that thin in terms of the use of our decision DX melanoma test. There are also patients that are coming in with invasive melanoma So a thickness of 0.1, 0.2, 0.3 or thicker who might have gotten diagnosed earlier with what we would call in situ or non-invasive melanoma, which is really just on the epidermal layer of the skin. We don't test those with our tests. So over time, It's our belief that as these patients begin to come back either to see their primary care doctor in person on a more routine basis or work their way into a dermatology practice, we'll be seeing more patients diagnosed who will actually hit the sweet spot of our test. But that hasn't happened at least yet. But it has to happen sometime because melanoma continues to go ahead and progress and evolve.

Gotcha. That's helpful. And then I just have one follow-up. Are there any updates in terms of your non-skin cancer programs that are underway? Is there any changes in terms of the timeline of what you have discussed in the past?

No. We've seen – I think we discussed this maybe at a conference here in the fall. So we have yet to disclose a couple of our other targets, but all of our programs right now are running – out of our internal estimate forecast. I believe that what we're seeing is that most of our pipeline programs are being executed at more high research organizations that are community-based versus hospital-based, and they seem to have sort of come out of COVID ready to start new protocols, I guess you would say, and they're seeing patients. So we don't see any delay in terms of timelines of our earlier estimates earlier this year.